In this episode, we dig into Teva Pharmaceuticals’ recent M&A and debate the single most important number reported in Gilead Sciences’ second-quarter earnings results.
In this episode, we dig into Teva Pharmaceuticals’ recent M&A and debate the single most important number reported in Gilead Sciences’ second-quarter earnings results.